BridgeBio Pharma Inc

BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BridgeBio Pharma Inc (NASDAQ: BBIO) estimates between $23 million to $25 million in restructuring-related costs, including write-offs of long-lived assets, severance and employee-related costs, and exit and other related costs. “The restructuring initiative included, among.

BridgeBio Shares Plunge After it Details Out-Licensing Plans For 'Restructuring Initiative'

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -5.31% and 80.59%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Reports Q1 Loss, Misses Revenue Estimates

–Completed sale to Sentynl Therapeutics of BridgeBio's NULIBRY™ (Fosdenopterin) for Injection –Updated strategic collaboration with Helsinn Group to develop, manufacture and commercialize infigratinib in oncology indications in the U.S.; BridgeBio is eligible to receive regulatory and commercial milestone payments as well as tiered royalties on adjusted net sales from Helsinn –Released positive data from Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), which demonstrated a 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline measured across all three dosing cohorts, signifying the oral therapy has the potential to address both the root cause of LGMD2i and drive functional improvements for patients –Reported data from ongoing Phase 2 open-label extension (OLE) study of acoramidis (AG10) in patients with symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) which demonstrated acoramidis continued to be well-tolerated and potently stabilize TTR, deepening BridgeBio's conviction in its Month 30 readout given the stability or improvement with respect to key cardiac biomarkers –Ended quarter with  $633.5 million in cash, cash equivalents and marketable securities, providing financial runway into 2024

BridgeBio Pharma Reports First Quarter 2022 Financial Results and Business Update

- NT-proBNP, a biomarker of cardiac failure and independent predictor of mortality in ATTR-CM patients, was stable or improving throughout the study. At Month 30, median change from baseline in NT-proBNP was -437 pg/mL with 68% of participants observing NT-proBNP levels below their baseline

BridgeBio Pharma Presents Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

PALO ALTO, Calif., March 28, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that updated data from its ongoing Phase 2 open-label extension (OLE) study of acoramidis (AG10) in patients with symptomatic transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM) will be featured in an oral presentation at the American College of Cardiology (ACC) Annual Scientific Session & Expo, taking place in Washington, D.C. on April 2 – 4, 2022.

BridgeBio Pharma to Present Updated Results from Phase 2 Open-label Extension Study of Acoramidis in Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the American College of Cardiology (ACC) Annual Scientific Session & Expo

First patient dosed in phase 1/2 ADventure study which is using BBP-631 for the treatment of patients with congenital adrenal hyperplasia; results from the study expected 2nd half of 2022.

BridgeBio: Potential Based On Diverse Pipeline Targeting KRAS Mutations And Rare Diseases

BridgeBio Pharma Inc (NASDAQ: BBIO) has announced data from the Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i), a group of conditions that cause weakness and wasting of the muscles in the arms and legs. The Company plans to engage with.

BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market

- 43% increase in the ratio of glycosylated alpha-dystroglycan (αDG) to total αDG from baseline were measured across all three dosing cohorts, signifying the oral therapy has the potential to address both the root cause of LGMD2i and drive functional improvements for patients - Average of 70% reduction in creatine kinase (CK), a key marker of muscle breakdown, after 90 days of treatment and average 77% reduction after 180 days - Increase in velocity in the 10-meter walk test (10MWT) at day 90 and 180, which is an improvement over the decline in velocity seen in the natural history data - If  the development program is successful, BridgeBio believes BBP-418 could be the first approved therapy for the treatment of patients with LGMD2i - BridgeBio to host investor call on March 14, 2022 at 8:00 AM ET

BridgeBio Pharma Announces Positive Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

PALO ALTO, Calif., March 11, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that it will host an investor call on March 14, 2022, at 8:00 AM ET to discuss data from its Phase 2 study of BBP-418 in patients with limb-girdle muscular dystrophy type 2i (LGMD2i). The results will be featured at the Muscular Dystrophy Association (MDA) 2022 Annual Meeting, taking place in Nashville, Tennessee on March 13 – 16, 2022.

BridgeBio Pharma, Inc. to Host Investor Call to Discuss Phase 2 Data for Limb-girdle Muscular Dystrophy Type 2i (LGMD2i)

PALO ALTO and SOLANA BEACH, Calif., March 08, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), a commercial-stage biopharmaceutical company that focuses on genetic diseases and cancers, and Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases owned by Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), today announced the execution of an asset purchase agreement (the Agreement) for the sale of BridgeBio's NULIBRY™ (Fosdenopterin) for Injection. NULIBRY is approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A, an ultra-rare, life-threatening pediatric genetic disorder. The closing of the asset purchase is subject to customary closing conditions.

BridgeBio Pharma and Sentynl Therapeutics Announce Asset Purchase Agreement for BridgeBio Pharma's NULIBRY™ (Fosdenopterin)

BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -21.69% and 61.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

BridgeBio Pharma (BBIO) Reports Q4 Loss, Misses Revenue Estimates

–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio's financial runway into 2024

BridgeBio Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update

Adagio Therapeutics

Allakos Inc

Alnylam Pharmaceuticals

argenx

Bicycle Therapeutics Plc - ADR

BioMarin Pharmaceutical

Denali Therapeutics

Incyte

Intra-Cellular Therapies

Jasper Therapeutics

Mirati Therapeutics

Praxis Precision Medicines

SAGE Therapeutics

Biotechnology is so beaten down, relative valuation metrics suggest some stocks could more than double

12 biotech stocks to consider buying now as prospects for the sector brighten this year

BridgeBio Pharma (BBIO) closed the most recent trading day at $9.04, moving +1.01% from the previous trading session.

BridgeBio Pharma (BBIO) Gains But Lags Market: What You Should Know

BridgeBio (BBIO) doses the first patient in a phase I/II study evaluating its investigational gene therapy candidate, BBP-631, for treating classic congenital adrenal hyperplasia.

BridgeBio (BBIO) Begins Dosing with Gene Therapy in CAH Study

- If successful, BridgeBio's investigational gene therapy BBP-631 would be the first therapy for CAH to restore the body's hormone and steroid balance by enabling people with CAH to make their own cortisol and aldosterone

BridgeBio Pharma Announces Dosing of First Patient in Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH)

Amgen

BridgeBio (BBIO) forges an alliance with Amgen to evaluate their respective cancer drugs for the treatment of advanced solid tumors with KRAS G12C mutations.

BridgeBio (BBIO), Amgen Partner in Advanced Solid Tumors Study

- First clinical combination study of BBP-398 and LUMAKRAS set to evaluate safety and preliminary efficacy in solid tumors with the KRAS G12C mutation

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

The company has over 5 data readouts from its diverse pipeline in 2022. The stock is recovering from the drop after the recent amyloidosis data.

Buying BridgeBio Pharma On The Drop After Phase 3 Amyloidosis Failure

BridgeBio Pharma (BBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

BridgeBio Pharma (BBIO) Moves 14.6% Higher: Will This Strength Last?

This company's market value plunged by around $8 billion in 2021, leading contrarian investors to suspect a bargain opportunity.

Is BridgeBio Pharma Stock a Buy on the Dip?

BridgeBio Pharma Inc (NASDAQ: BBIO) is trading higher Tuesday as the stock rebounds after falling on Monday.  BridgeBio Pharma shares traded lower Monday after the company announced that its Phase 3 trial to treat symptomatic transthyretin amyloid cardiomyopathy did not achieve its primary endpoint.

Why BridgeBio Pharma Shares Are Rising

BridgeBio's (BBIO) acoramidis fails to meet the primary endpoint of a six-minute walk test in cardiomyopathy patients. However, secondary data demonstrate a favorable trend.

BridgeBio (BBIO) Tumbles on Cardiomyopathy Candidate Failure

Investors are more than a little disappointed with a phase 3 clinical trial failure.

Why Bridgebio Pharma Stock Is Imploding on Monday

BridgeBio Pharma Inc (NASDAQ: BBIO) is trading significantly lower Monday morning after the company announced that its Phase 3 trial to treat symptomatic transthyretin amyloid cardiomyopathy did not achieve its primary endpoint. The ATTRibute-CM independent data monitoring committee recommends continuing the study based on unblinded data reviews.

News for BridgeBio Pharma Inc Stock (BBIO)